- A study published in the Journal of Cardiac Failure used Truveta Data to examine initial diuretic treatment strategies among more than 109,000 patients hospitalized for heart failure.

- Patients treated with more intensive diuretic strategies experienced greater weight loss during hospitalization, indicating more effective fluid removal. These strategies were also associated with higher rates of acute kidney injury.

- Regardless of treatment strategy, greater weight loss during hospitalization was associated with lower odds of readmission or death within 90 days.

Heart failure is one of the most common causes of hospitalization in the United States. A central goal of inpatient management is relieving congestion by removing excess fluid, typically through treatment with loop diuretics. While clinical guidelines provide general recommendations, clinicians use a wide range of dosing and combination strategies in practice, particularly for patients with more severe disease.

A new study published in the Journal of Cardiac Failure examined how different initial diuretic strategies were associated with fluid removal, kidney injury, and outcomes after discharge.

Study snapshot

Researchers identified more than 109,000 patients hospitalized for heart failure between 2015 and 2022 across US health systems in Truveta Data. Patients were grouped based on the most intensive diuretic strategy used within the first 48 hours of hospitalization, ranging from low-dose loop diuretics alone to high-dose loop diuretics combined with adjuvant therapies such as thiazides or acetazolamide.

Researchers examined weight loss, hemoconcentration, acute kidney injury during hospitalization, and the combined outcome of readmission or death within 90 days.

More intensive treatment was associated with greater fluid loss, but also higher rates of kidney injury

Patients treated with more intensive diuretic strategies also experienced greater weight loss during hospitalization, suggesting more effective removal of excess fluid. The largest reductions were observed among patients receiving high-dose loop diuretics combined with adjuvant therapy, with an adjusted average weight loss of 4.6 pounds.

However, more intensive treatment was also associated with higher rates of acute kidney injury during hospitalization, highlighting the clinical tradeoffs that can accompany more aggressive decongestion strategies.

Greater weight loss was associated with better outcomes after discharge

Despite greater weight loss during hospitalization, more intensive diuretic treatment strategies were not associated with lower odds of readmission or death within 90 days.

Researchers also evaluated weight loss itself, regardless of which diuretic strategy was used. They found that patients who lost more weight during hospitalization had lower odds of readmission or death within 90 days. Specifically, every five pounds of weight loss was associated with lower adjusted odds of the combined outcome.

This relationship was observed across treatment groups, suggesting that patients who lost more weight during hospitalization generally had better outcomes after discharge, regardless of how that weight loss was achieved.

Read the full study

Initial Diuretic Strategy During Hospitalization for Heart Failure and Associated Outcomes: Insights From the TREAT-AHF Registry, Journal of Cardiac Failure

- Although traditional bicycle-related ED visits remained far more common, e-bike injury rates increased 760.2% between 2023 and August 2026, while traditional bicycle injuries remained relatively stable, increasing only 7.9%.

- Among children and adolescents, the e-bike-related ED visit rate increased 19.1-fold, compared with a 1.5-fold increase for traditional bicycles.

- Traumatic brain injury was diagnosed in 7.8% of e-bike-related ED visits among patients younger than 18 years, compared with 6.0% of traditional bicycle ED visits.

In our recent analysis of e-bike- and e-scooter-related emergency department (ED) visits, we found a 7.5-fold increase in the rate of visits among children and adolescents over the past 3 years. As a follow-up, we wondered how e-bike-related emergency department visits compared with traditional bicycle-related visits, especially in summer months.

Comparing e-bikes with traditional bicycles provides important context for these trends. E-bikes can travel faster than traditional bicycles, and research indicates e-bike owners rode longer distances and took more trips per week than traditional bike owners (3–6). Collision data also found that e-bike collisions more often involved unsafe speeds and improper turning violations compared to traditional bike collisions (3, 6). While recent national research found that e-bike injury-related ED visits increased much faster than traditional bicycle visits through 2024 (1, 2), more recent data are limited. Although e-bike injury patterns are generally similar to those associated with traditional bicycles, several studies have found that e-bike crashes are more likely to result in severe outcomes, including head and facial injuries, traumatic brain injuries, and critical trauma or intensive care treatment (3–6). Notably, helmet use among injured e-bike riders has been reported in only about 31% of cases, and varied by age (7). However, findings have not been entirely consistent, and much of the comparative research used data prior to the recent spike in e-bike injuries among children and adolescents (3, 6).

Using a subset of Truveta Data, we examined e-bike- and traditional bicycle-related ED visits over time and across age groups, then compared patient characteristics, injured body regions, injury types, and rate of traumatic brain injuries.

Methods

We used a subset of Truveta Data to identify ED visits with diagnosis codes indicating involving an e-bike or a traditional bicycle from January 2023 through August 2026. ED visits were required to be at least 30 days apart to increase confidence that the visits were for different bike injuries.

We calculated monthly rates of individuals with an ED visit related to an e-bike or traditional bike injury visit per 100,000 people with an ED visit. We stratified results by age group (0–17, 18–24, 25–44, 45–64, and 65 years or older). Because the study period included data only through August 2026, we compared only the January–August period across years to account for seasonal changes in e-bike and e-scooter use.

To characterize injuries, we evaluated all injury diagnoses recorded on the same day as the bike injury ED visit. Injury diagnoses were categorized using the National Center for Health Statistics ICD-10-CM Injury Diagnosis Matrix, which classifies injuries according to both body region and injury type.

Body regions were grouped into the following categories:

- Head and neck

- Shoulder and upper arm

- Forearm and elbow

- Wrist, hand, and fingers

- Trunk

- Hip, upper leg, and thigh

- Knee

- Lower leg and ankle

- Foot and toes

Injury types were categorized as:

- Superficial injuries and contusions

- Fractures

- Open wounds

- Sprains and strains

- Traumatic brain injuries (including concussions)

- Dislocations

- Internal organ injuries

- Other injuries

As patients can receive multiple injuries during a single event, individuals could contribute to multiple injury categories and types.

Results

Traditional bicycle-related ED visits were far more common than e-bike-related ED visits during the study period, with 63,811 traditional bicycle-related ED visits compared with 4,769 e-bike-related ED visits. Nearly 1 in 3 e-bike (31.1%) and traditional bicycle (29.3%) injuries occurred in patients under 18 years of age. Adults aged 18–24 years represented a larger share of e-bike visits than traditional bicycle visits (15.0% vs. 9.8%), whereas adults aged 65 years or older represented a smaller share (7.0% vs. 11.3%). 75.9% of e-bike patients and 76.3% of traditional bicycle patients were male.

E-bike and traditional bicycle-related ED visit rates

The rate of e-bike-related ED visits increased from 1.2 per 100,000 people with an ED visit in January–August 2023 to 10.1 per 100,000 in January–August 2026, representing a 760.2% increase. The traditional bicycle rate remained stable, increasing only 7.9%, from 59.4 to 64.1 per 100,000 over the same period.

E-bike and traditional bike-related ED visit rates by age group

Across the study period, bicycle-related ED visit rates were highest among younger age groups for both e-bikes and traditional bicycles. Overall, rates of e-bike-related ED visits were highest among patients aged 0-17 years (11.4 per 100,000 people with an ED visit) and 18-24 years (7.9 per 100,000), while rates declined with increasing age. A similar pattern was observed for traditional bicycle-related ED visits, with the highest rates among patients aged 0-17 years (143.3 per 100,000) followed by those aged 18-24 years (69.0 per 100,000).

E-bike-related ED visit rates increased across every age group. The largest relative increase occurred among patients aged 0–17 years; the rate increased from 1.9 per 100,000 people with an ED visit in January–August 2023 to 35.7 per 100,000 in January–August 2026, representing a 19.1 fold increase. Rates also increased among adults aged 18–24 years (7.7 fold), 25–44 years (7.4 fold) 45–64 years (7.6 fold), and 65 years or older (3.2 fold).

Similar to the overall rate, traditional bicycle-related ED visit rates for each age group changed less over the study period. From January-August 2023 to January-August 2026, rates increased 1.45-fold among patients aged 0-17 years, 1.19-fold among adults aged 18-24 years, and 1.09-fold among adults aged 25-44 years. Rates among adults aged 45-64 years and 65 years or older were 0.92-fold and 0.95-fold of their January-August 2023 levels, respectively.

Injuries associated with e-bikes and traditional bicycles

Injury patterns were broadly similar between e-bike and traditional bicycle injuries. For injuries where the type could be specified, superficial injuries and contusions were the most frequently diagnosed injury type, occurring in 35.0% of e-bike injury visits and 39.9% of traditional bicycle injury visits. Fractures were the second most common diagnosis and were slightly more prevalent among e-bike injuries (28.3% vs. 25.1%). Rates of traumatic brain injury were comparable between groups (5.8% vs. 5.6%).

Traumatic brain injuries

Among patients younger than 18 years, traumatic brain injury was diagnosed in 7.8% of e-bike-related ED visits and 6.0% of traditional bicycle-related visits. Percentages were more similar among adults aged 18–24 years (5.4% vs. 5.7%) and 25–44 years (5.3% vs. 4.8%). Among adults aged 45–64 years and 65 years or older, traumatic brain injury was less common in e-bike visits than traditional bicycle visits (3.9% vs. 5.6% and 4.2% vs. 6.7%, respectively).

Discussion

In this follow-up analysis, we found that higher rates of ED visits for injuries involving traditional bicycles compared with e-bikes. However, we also found the rate of e-bike-related ED visit rates rose 8.4-fold from 2023 to 2026, compared with only a 1.1-fold increase for traditional bicycles.

This pattern is consistent with recent national research showing that electric micromobility injuries are increasing much faster than traditional bicycle injuries (1, 2). Using US emergency department surveillance data, a previous analysis found that e-bike injury visit counts increased 389% from 2020 to 2024, compared with 6.4% for bicycles (2). Our analysis extends those findings through August 2026 and shows that the difference in growth persisted, with the e-bike visit rate increasing 760.2% compared with 7.9% for traditional bicycles. ED visits associated with e-bikes increased across every age group, but the increase was most pronounced among children and adolescents under 18 years, whose rate rose approximately 19.1-fold, compared with a 1.5-fold increase for traditional bicycles.

Our injury findings provide additional context on how e-bike and traditional bicycle visits compare. Injuries involving the head and neck were the most common injury location for both groups, accounting for nearly one-third of visits. Although head and neck injuries were less common among e-bike visits than traditional bicycle visits, traumatic brain injuries were more common among e-bike visits among patients younger than 18 years. Several differences in injury patterns were also observed. Fractures represented a larger percentage of e-bike visits. E-bike visits were more likely to involve injuries to the wrist, hand, and fingers, lower leg and ankle, and foot and toes, whereas shoulder and upper arm and trunk injuries were more common among traditional bicycle visits. These findings suggest that while head injuries remain a major contributor to both e-bike- and bicycle-related ED visits, injury patterns may differ in important ways between the two bicycle types. These results are consistent with prior studies describing fractures as a substantial component of e-bike injuries (8, 9). One national analysis estimated that e-bike-related fractures increased sharply from 2019 to 2023 and found that the wrist was the most common fracture location among riders younger than 18 years (8).

Today, Truveta was featured on LinkedIn’s 2026 Top Startups list in Seattle. The annual ranking highlights emerging companies in the Seattle region that are attracting talent, growing quickly, and building momentum.

This is the fourth consecutive year Truveta has been recognized on LinkedIn’s Top Startups list. We are honored by the recognition and grateful to the many Truvetans whose talent, dedication, and passion for our mission make achievements like this possible.

The Greater Seattle area has long been a global center of technology innovation, and we are proud to call the Pacific Northwest home. The region’s deep talent, entrepreneurial spirit, and commitment to innovation have helped shape Truveta from the beginning. As we continue to grow, we remain committed to building a culture where mission-driven people can do the best work while making a meaningful impact on health. Today, Truveta has more than 500 employees globally.

LinkedIn’s Top Startups list is determined using exclusive LinkedIn data and evaluates companies across four pillars, employment growth, engagement, job interest and attraction of top talent. Eligible companies must be privately held, independent, headquartered in the United States, seven years old or younger, and have at least 30 full-time employees in the metro area.

We are thankful to LinkedIn for this recognition and grateful to our team, health system members, customers, partners, and broader community who support our mission.

Interested in joining us? Visit our Careers page to learn more about open opportunities and help advance our mission of Saving Lives with Data.

When I joined Truveta earlier this year, I was inspired by something bigger than data, technology, or even scientific advancement.

I was inspired by collaboration.

Truveta was founded because leading health systems came together during a global pandemic around a simple but powerful idea: healthcare should learn faster. Rather than keeping knowledge siloed, they chose to build a way for patient experiences, clinical insights, and research discoveries to contribute to something larger than any one institution.

Over the past few months, I have met with numerous academic and health system leaders, and a common theme that emerged from every conversation is that most important advances in medicine happen when communities learn together.

Researchers build on one another’s discoveries. Health systems share best practices. Industry, academia, and care providers collaborate to answer questions no single organization can solve alone. Progress accelerates when knowledge becomes collective.

Improving patient care shouldn’t always mean waiting for the next prospective clinical trial. Healthcare generates extraordinary knowledge every day. Every patient encounter creates an opportunity to learn something that could help improve care for the next patient. The challenge is ensuring those lessons travel farther than the institutions where they originate. Too often, evidence remains fragmented, insights move too slowly, and opportunities to improve care are missed.

The future of healthcare requires a learning system where healthcare learns and improves from every patient, every day; where each encounter contributes to collective knowledge; where every discovery advances better care; and where collaboration becomes a force multiplier for innovation.

The Truveta Genome Project reflects that philosophy. The Truveta Genome Project aspires to create the largest and most diverse de-identified database of exome-wide genomic data linked to high fidelity clinical data ever assembled. Yet, at its core, the project is not simply about genomics. It is about what can happen when health systems unite around a shared commitment to advancing care. By connecting genomic information with rich longitudinal clinical data, participating health systems are helping create opportunities to better understand the relationship between biology, disease, treatments, and outcomes. The depth of data contributed by health systems helps create a more complete picture of the patient, allowing researchers to better understand not only what happened, but why.

It demonstrates how collaboration at scale can create new foundations for discovery.

The future of healthcare will increasingly depend on connecting multiple dimensions of patient health.

Clinical data help us understand what happened across a patient’s journey. Genomic data help us understand biology. Imaging data provide another critical perspective on disease progression and treatment response. Individually, each source provides valuable information. Together, they create a more complete picture of the patient and a deeper understanding of health and disease, opening new possibilities for research, evidence generation, and better care.

The greatest breakthroughs ahead will not come from any single company, health system, researcher, or technology. They will come from all of us learning together.

Because when healthcare learns faster, patients benefit sooner. And that’s a future worth building together, creating a future where each patient contributes to collective knowledge and every new insight helps improve care for the patients who follow.

- A study presented at EASD 2026 used Truveta Data to examine mortality and cardiovascular outcomes among nearly 28,000 adults with type 2 diabetes on basal insulin.

- CGM use was associated with a 45% lower risk of death at one year and a 36% lower risk of death at two years compared with non-users.

- Researchers also found lower risks of cardiovascular events, including heart attack, stroke, peripheral artery disease, and heart failure hospitalization.

As continuous glucose monitoring (CGM) use expands among people with type 2 diabetes, researchers are increasingly exploring its association with outcomes beyond glucose control. A study presented at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting used Truveta Data to evaluate long-term outcomes among nearly 28,000 adults with type 2 diabetes receiving basal insulin therapy.

Using longitudinal electronic health record (EHR) and mortality data, researchers conducted a target trial emulation comparing outcomes between CGM users and non-users.

CGM use was associated with lower mortality and fewer cardiovascular events

At one year, CGM users had a 45% lower risk of death from any cause compared with people who did not use CGM. At two years, the risk remained 36% lower.

Researchers also found lower risks of cardiovascular events, including heart attack, stroke, peripheral artery disease, and heart failure hospitalization. Heart failure hospitalizations were approximately half as common among CGM users at both one and two years.

Because this was an observational study, the findings show an association and cannot determine whether CGM directly caused the lower rates of death or cardiovascular events.

Read more

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients, presented at EASD 2026.

By Kristin Rand, PhD, MPH, Senior Director of Genomics Partnerships at Truveta

Over the last 15 months, I’ve been focused on building the foundation for the Truveta Genome Project, an ambitious collaboration with participating health systems to create a consented, de-identified genomic dataset linked with longitudinal clinical data. By connecting genetic information with patients’ clinical data, treatments, and outcomes over time, we aim to help researchers accelerate discovery and advance more precise care.

Since we announced the project, we have moved from planning to enrolling participants and collecting samples. This progress has given me a moment to reflect on what we are building, its potential impact on health research, and where we go from here.

Building the foundation

When I think about where the Truveta Genome Project is today, I am most proud of the solid foundation we’ve built. The most important aspect of our research is the patient, from the beginning stages of informed research consent to the long-term impact we hope to have on all patients. With that in mind, we have developed a robust, patient-centered protocol and informed consent process for the genetic samples we’re collecting, making sure our participants are aware and informed of the research we plan to do and the impact we hope to have on human health overall. We have also partnered closely with each of our participating health systems to provide the support and structure needed for large-scale research, while providing the autonomy needed to meet specific research and clinical needs.

These early steps have been complex, but this level of rigor at the outset is essential to building an ethical, robust, and scalable program. If we want to build something that serves patients, earns trust, and lasts, we must get the foundation right.

What makes this possible is the same thing that has made Truveta unique since our founding. Truveta was built by health systems whose people believed they could accomplish more together than they could alone. This shared commitment gave rise to Truveta, and today that sense of community powers the Truveta Genome Project.

Understanding the whole patient

Genomics holds extraordinary promise, but its clinical power depends entirely on context. The true value of a genetic variant emerges only when linked to phenotypes, treatments, and outcomes across large, diverse populations over time, capturing the full patient journey. The potential of the Truveta Genome Project lies in understanding genomic variation within the context of real-world patient experiences over time.

By combining genomic and longitudinal clinical data at an unprecedented scale, we can move beyond population averages and answer crucial questions like, why does disease manifest differently across patients? Why do two patients on the same therapy experience vastly different outcomes? How do we better understand disease risk within and across diverse populations, and how do we detect this risk earlier, before irreversible harm occurs?

Honoring patient trust

Health system participation sends a powerful signal to patients. It shows that this effort is grounded in the same organizations caring for patients every day. By inviting patients to participate in the Truveta Genome Project, our health systems are helping build a resource that will allow medicine to learn faster, act sooner, and deliver care that is more precise, more predictive, and more equitable.

As trusted healthcare providers, our health system members lead participant enrollment and informed consent, helping patients understand what participation means and make informed decisions about contributing to research. That direct connection to patients provides the clinical and ethical foundation that makes the Truveta Genome Project possible.

The Truveta Genome Project reflects Truveta’s longstanding commitment to Saving Lives with Data and investing in the future of precision medicine.

Creating a national research resource

The Truveta Genome Project operates under a centralized multi-site research protocol, in which Truveta serves as the study sponsor, and each participating health system assigns its own site principal investigator upon enrollment.

This approach reduces administrative burden and accelerates deployment, while still allowing health systems to maintain local oversight. Health systems have the flexibility to meet local requirements without sacrificing the benefits of participating in a large-scale national genomics initiative.

As more health systems join the project, we will continue refining our approach to scale responsibly while maintaining the principles that guided its design. Greater scale will also enable researchers to study genomic information alongside other types of biological and clinical data, opening new avenues for discovery.

Representation at scale

Our ambitious goal for the Truveta Genome Project is to enroll tens of millions of consenting participants and create the largest and most diverse database of genotypic and phenotypic information ever assembled. This diversity will lead to discoveries that affect ALL patients, not just those with certain diseases or specific ancestral backgrounds.

The project is powered by participating health systems and the patients and communities they serve, bringing together people from across the country to help build a resource that reflects the real world. Bringing together participants from diverse communities will help researchers better understand how genetic variation influences disease risk, treatment response, and outcomes across populations.

That is the future we are building toward. The foundation is in place, and we are only just getting started.

Skip to main content

What We Do

AI & Data Readiness

Advanced Engineering & innovation

Cyber & IT Solutions

Operations & Logistics

Modernization & Sustainment

Training

Readiness

Who We Serve

Defense

National Security

Aerospace & Aviation

Commercial & Emerging Markets

Global Operations & Infrastructure

About Us

About V2X

Leadership

Environment, Health, and Safety Policy

Code of Conduct

Careers

Open Positions

Investors

Contact

Search

Newsroom

Suppliers

Contract Vehicles

Contact Us

What We Do

AI & Data Readiness

Advanced Engineering & innovation

Cyber & IT Solutions

Operations & Logistics

Modernization & Sustainment

Training

Readiness

Who We Serve

Defense

National Security

Aerospace & Aviation

Commercial & Emerging Markets

Global Operations & Infrastructure

About Us

About V2X

Leadership

Environment, Health, and Safety Policy

Code of Conduct

Careers

Open Positions

Investors

Newsroom

Suppliers

Contract Vehicles

Contact Us

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SFAF Meeting | Presentation of H1 2026 Resultshttps://www.sword-group.com/wp-content/uploads/2026/07/1200x900_SiteWeb_SFAF-H12026-10092026_Page_2.jpg1116837Stéphanie DesmarisStéphanie Desmarishttps://secure.gravatar.com/avatar/91f978ec734595032f8919318e5b63d47f60fb362b59d7b470b0363812657e08?s=96&d=mm&r=g03/07/202610/07/2026

—–

SFAF Meeting | Presentation of H1 2026 Results

—–

The SFAF meeting to present the results for H1 2026 will take place on 10 September at 10am. We will be meeting you in Lyon at Pathé Lyon Vaise | 43 Rue des Docks, 69009 Lyon.

You also have the option to attend the meeting remotely. Please indicate your preference in the registration form below.

First name

Last name

Company

Position

Professional email address

How would you prefer to attend (If available)? In PersonOnline

I provide my contact information so that Sword Group will register me for its event. I understand that I can ask them to stop all communication at any time. How?

DALLAS, Oct. 26, 2026 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) (the "Company") today announced that it has priced an underwritten public offering of $1,250,000,000 aggregate principal amount of its senior notes, consisting of $600,000,000 aggregate principal amount of 5.750% Notes due 2029 (the "2029 Notes") and $650,000,000 aggregate principal amount of 6.000% Notes due 2031 (the "2031 Notes" and, collectively with the 2029 Notes, the "Notes").

The Company expects to use the net proceeds from the offering for general corporate purposes, which may include, but are not limited to, the repayment at maturity of all of the Company's outstanding $300 million aggregate principal amount of 3.000% notes due November 15, 2026, as well as the repayment or redemption of other indebtedness or other corporate obligations. The offering is expected to close on or about November 2, 2026, subject to customary closing conditions.

Barclays Capital Inc., BNP Paribas Securities Corp., Standard Chartered Bank, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. A shelf registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and has become effective. The offering may be made only by means of a prospectus supplement and an accompanying base prospectus. The preliminary prospectus supplement and accompanying base prospectus relating to the offering have been filed, and a final prospectus supplement will be filed, with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained from (1) Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019, United States of America, Attention: Syndicate Registration, Facsimile: (646) 834-8133; (2) BNP Paribas Securities Corp., 787 Seventh Avenue, New York, New York 10019, Attention: Debt Syndicate Desk, Email: [email protected]; (3) Standard Chartered Bank, One Basinghall Avenue, London EC2V 5DD, United Kingdom, Tel: +44 207-885-8888, Email: [email protected], Attention: Capital Markets; (4) U.S. Bancorp Investments, Inc., 214 N. Tryon Street, 26th Floor, Charlotte, North Carolina 28202, Attention: Credit Fixed Income, Facsimile: (877) 774-3462; and (5) Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, Minnesota 55402, Attention: WFS Customer Service, Email: [email protected], Toll-Free: (800) 645-3751.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

About Southwest Airlines Co.

Southwest Airlines Co. operates Southwest Airlines, a major passenger airline that provides scheduled air transportation in the United States and near-international markets. We commenced service on June 18, 1971, with three Boeing 737 aircraft serving three Texas cities: Dallas, Houston, and San Antonio. As of September 30, 2026, we had a total of 803 Boeing 737 aircraft in our fleet and served 120 destinations in the United States and near-international countries.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Specific forward-looking statements include, without limitation, statements related to the proposed terms of the offering described herein, the completion, timing, and size of the proposed offering, and the anticipated use of proceeds from the offering. Forward-looking statements involve risks, uncertainties, assumptions, and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Factors include, among others, (i) the impact of geopolitical conflicts, fears or actual outbreaks of diseases, extreme or severe weather and natural disasters, actions of competitors (including, without limitation, pricing, scheduling, capacity, and network decisions, and consolidation and alliance activities), governmental actions, consumer perception, consumer uncertainties with respect to trade policies, tariffs, or government shutdowns, economic conditions, fears or actual acts of terrorism or war, sociodemographic trends, and other factors beyond the Company's control, on consumer behavior and the Company's results of operations and business decisions, plans, strategies, and results; and (ii) other factors, as described in the Company's filings with the SEC, including the detailed factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant stock exchange rules, the Company expressly disclaims any obligation to disseminate, after the date of this press release, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.

SOURCE Southwest Airlines Co.

Share this article

Financial Announcement | Availability of the H1 2026 Financial Report Financial Announcement | Availability of the H1 2026 Financial Report https://www.sword-group.com/wp-content/uploads/2026/10/1200x900_SiteWeb_Rapport-Fi-H1-2026_Page_1.jpg 1059 794 Kieran Parnell Kieran Parnell https://secure.gravatar.com/avatar/fb93375d72c13dbc88229861ab51c13def8014a1c1edf0b64b861f95e2a862f3?s=96&d=mm&r=g 28/08/2026 02/10/2026 Financial Announcement | Availability of the H1 2026 Financial Report Find all the H1 2026 results of Sword Group in the financial report! READ THE PRESS RELEASE READ THE FINANCIAL REPORT